Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.05B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.61B |
| 3 |
Tesla
TSLA
|
+$636M |
| 4 |
TSMC
TSM
|
+$604M |
| 5 |
iShares Bitcoin Trust
IBIT
|
+$330M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.25B |
| 2 |
Apple
AAPL
|
+$1.13B |
| 3 |
Microsoft
MSFT
|
+$988M |
| 4 |
Meta Platforms (Facebook)
META
|
+$572M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$570M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.55% |
| 2 | Consumer Discretionary | 0.95% |
| 3 | Financials | 0.77% |
| 4 | Healthcare | 0.67% |
| 5 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PLG
12126
PUT
Platinum Group Metals
PLG
$203M
| $18.7K | ﹤0.01% |
15,100
+5,100
| +51% | +$6.55K |
|
12127
PUT
Nektar Therapeutics
NKTR
$2.56B
| $18.7K | ﹤0.01% |
+1,833
| New | +$23.9K |
|
12128
Calidi Biotherapeutics
CLDI
$3.39M
| $18.5K | ﹤0.01% |
170
+50
| +42% | +$9.12K |
|
12129
CytomX Therapeutics
CTMX
$734M
| $18.3K | ﹤0.01% |
28,734
-31,044
| -52% | -$24.1K |
|
|
SOL
12130
DELISTED
Emeren Group
SOL
| $18.2K | ﹤0.01% |
11,561
-73,047
| -86% | -$128K |
|
12131
PUT
Sypris Solutions
SYPR
$41.4M
| $18K | ﹤0.01% |
+11,200
| New | +$21.8K |
|
|
KYNB
12132
Kyntra Bio
KYNB
$32.8M
| $18K | ﹤0.01% |
2,327
-3,041
| -57% | -$36.5K |
|
12133
Artelo Biosciences
ARTL
$3.3M
| $17.8K | ﹤0.01% |
+1,133
| New | +$22.8K |
|
12134
AYTU BioPharma
AYTU
$25.2M
| $17.8K | ﹤0.01% |
+14,865
| New | +$21.6K |
|
12135
Q32 Bio
QTTB
$486M
| $17.8K | ﹤0.01% |
+10,810
| New | +$29.1K |
|
12136
PUT
FingerMotion
FNGR
$10.5M
| $17.8K | ﹤0.01% |
13,000
-142,100
| -92% | -$183K |
|
|
TMQ
12137
Trilogy Metals
TMQ
$663M
| $17.8K | ﹤0.01% |
+11,469
| New | +$15.8K |
|
|
ELEV
12138
DELISTED
Elevation Oncology
ELEV
| $17.7K | ﹤0.01% |
68,437
+30,512
| +80% | +$17.4K |
|
|
HOFV
12139
DELISTED
Hall of Fame Resort & Entertainment Co
HOFV
| $17.7K | ﹤0.01% |
+21,287
| New | +$22.9K |
|
12140
CALL
Passage Bio
PASG
$15.5M
| $17.6K | ﹤0.01% |
2,515
+1,990
| +379% | +$21.5K |
|
12141
Network-1 Technologies
NTIP
$35.4M
| $17.6K | ﹤0.01% |
13,519
+1,218
| +10% | +$1.67K |
|
|
CRESW
12142
DELISTED
Cresud SACIF y A. Warrant
CRESW
| $17.5K | ﹤0.01% |
+21,046
| New | +$20.4K |
|
12143
Performance Shipping
PSHG
$21M
| $17.4K | ﹤0.01% |
+10,830
| New | +$17.9K |
|
12144
PUT
Seres Therapeutics
MCRB
$50.2M
| $17.4K | ﹤0.01% |
1,245
-5,265
| -81% | -$82.4K |
|
|
SBDS
12145
DELISTED
Solo Brands Inc
SBDS
| $17.4K | ﹤0.01% |
2,595
+1,623
| +167% | +$49.7K |
|
|
UBX
12146
CALL
DELISTED
Unity Biotechnology
UBX
| $17.4K | ﹤0.01% |
+16,700
| New | +$30.2K |
|
|
PCTTW
12147
PureCycle Technologies Inc Warrant
PCTTW
| $17.3K | ﹤0.01% |
+11,191
| New | +$31.1K |
|
12148
Lulu's Fashion Lounge
LVLU
$39.9M
| $17.3K | ﹤0.01% |
2,890
+159
| +6% | +$1.79K |
|
12149
CALL
NanoViricides
NNVC
$32.9M
| $17.3K | ﹤0.01% |
+14,800
| New | +$18.8K |
|
12150
CALL
Actinium Pharmaceuticals
ATNM
$33.9M
| $17.2K | ﹤0.01% |
10,700
-3,700
| -26% | -$4.7K |
|
Similar funds
Jeff Yass's Q1 2025 Portfolio in Review
As of Q1 2025, Jeff Yass held 13,842 positions worth $586B, down 12% from $663B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass withdrew a net $24.4B in Q1 2025, closing 1,482 positions and reducing 4,842 holdings. Its most notable exit was Inari Medical, Inc. Common Stock, an estimated $24M position sold in full.
By sector, the portfolio is most concentrated in Technology at 1.6% of assets, down from 2% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jeff Yass opened a new position in Brookfield Asset Management worth $86M.
- Jeff Yass's largest Q1 2025 buy was Brookfield Asset Management: 1,775,684 shares worth $86M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $4.05B increase.
- Jeff Yass's biggest Q1 2025 reduction was Invesco QQQ Trust, cutting an estimated $1.25B.
- Jeff Yass fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $24M.
- Jeff Yass's ten largest holdings make up 28% of its $586B portfolio in Q1 2025.
- Jeff Yass opened 1,775 new positions and closed 1,482 in Q1 2025.
- Jeff Yass's portfolio value fell 12% quarter-over-quarter to $586B.
Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.